|
on in Dose May Be Recommended Based on Results from Drug Interaction Studies or Predicted InteractionsThis table is not all inclusive. (Information in the Table Applies to Co-administration of PREVYMIS and the Concomitant Drug without Cyclosporine, Unless Otherwise Indicated)Concomitant Drug Class and/or Clearance Pathway: Drug NameEffect on Concentration↓ =decrease, ↑=increaseClinical CommentsAnti-arrhythmic agentsamiodarone↑ amiodaroneClose clinical monitoring for adverse events related to amiodarone is recommended during co-administration. Frequently monitor amiodarone concentrations when amiodarone is co-administered with PREVYMIS.Anticoagulantswarfarin↓ warfarinWhen PREVYMIS is co-administered with warfarin, frequently monitor International Normalized Ratio (INR)Refer to the respective prescribing information..Anticonvulsantsphenytoin↓ phenytoinWhen PREVYMIS is co-administered with phenytoin, frequently monitor phenytoin concentrations.Antidiabetic agentsExamples:glyburide, repaglinide, rosiglitazone↑ glyburide↑ repaglinide↑ rosiglitazoneWhen PREVYMIS is co-administered with glyburide, repaglinide, or rosiglitazone, frequently monitor glucose concentrations.When PREVYMIS is co-administered with cyclosporine, use of repaglinide is not recommended.AntifungalsvoriconazoleThese interactions have been studied [see Clinical Pharmacology (12.3)].↓ voriconazoleIf concomitant administration of voriconazole is necessary, closely monitor for reduced effectiveness of voriconazole.Antimycobacterialrifampin↓ letermovirCo-administration of PREVYMIS and rifampin is not recommended.Antipsychoticspimozide↑ pimozideCo-administration is contraindicated due to risk of QT prolongation and torsades de pointes [see Contraindications (4)].Ergot alkaloidsergotamine, dihydroergotamine↑ ergotamine, dihydroergotamineCo-administration is contraindicated due to risk of ergotism [see Contraindications (4)].HMG-CoA Reductase Inhibitorsatorvastatin↑ atorvastatinWhen PREVYMIS is co-administered with atorvastatin, do not exceed an atorvastatin dosage of 20 mg daily. Closely monitor patients for myopathy and rhabdomyolysis.When PREVYMIS is co-administered with cyclosporine, use of atorvastatin is not recommended.pitavastatin, simvastatin↑ HMG-CoA reductase inhibitorsCo-administration of PREVYMIS and pitavastatin or simvastatin is not recommended.When PREVYMIS is co-administered with cyclosporine, use of either pitavastatin or simvastatin is contraindicated due to significantly increased pitavastatin or simvastatin concentrations and risk of myopathy or rhabdomyolysis [see Contraindications (4)].fluvastatin, lovastatin, pravastatin, rosuvastatin↑ HMG-CoA reductase inhibitorsWhen PREVYMIS is co-administered with these statins, a statin dosage reduction may be necessary. Closely monitor patients for myopathy and rhabdomyolysis.When PREVYMIS is co-administered with cyclosporine, use of lovastatin is not recommended.When PREVYMIS is co-administered with cyclosporine, refer to the statin prescribing information for specific statin dosing recommendations.Immunosuppressantscyclosporine↑ cyclosporine↑ letermovirDecrease the dosage of PREVYMIS to 240 mg once daily [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].Frequ |
